Trypanosoma cruzi, the parasite that causes Chagas disease, infects more than seven million people worldwide, with the heaviest burden concentrated in Latin America. In recent decades, migration and travel have turned the infection into a public health concern well beyond its traditional geographic boundaries, with cases now identified in the United States, Europe and Japan. Although the parasite often remains silent for years, roughly 30 to 40 percent of infected individuals eventually develop Chagas disease, which can lead to serious and potentially life-threatening heart or digestive complications. Despite the scale of the problem, fewer than one percent of infected people are ever diagnosed and treated, a gap driven by weak screening programs, stigma, and the poor tolerability of the drugs that exist.

Only two medicines are available against T. cruzi: benznidazole and nifurtimox. Both were developed in the 1960s and 1970s, and both are still administered according to dosing schedules that have barely changed since then. The standard benznidazole course requires patients to take the drug twice a day for 60 days, a demanding commitment for people who may live far from clinics or have jobs that make midday dosing difficult. More importantly, these prolonged regimens frequently cause adverse reactions ranging from skin rashes and digestive complaints to neurological symptoms, and up to 31 percent of patients abandon treatment before finishing it. Because treatment completion is essential for curing the infection, side effects and pill burden translate directly into treatment failure at the population level.

TESEO was designed to test whether alternative durations and dosing schedules could improve that equation. According to Igor Almeida of the University of Texas at El Paso, corresponding author and co-senior author of the study alongside Faustino Torrico of CEADES and Joaquim Gascón of ISGlobal, the trial was the first randomized clinical study to evaluate benznidazole and nifurtimox head-to-head under identical conditions, with sustained follow-up designed to detect parasites in the blood by PCR for three years. This long observation window matters because the parasite can persist at very low levels after treatment, and confirming sustained clearance requires patient monitoring that many earlier studies simply could not provide.

The phase 2b trial enrolled 450 adults at three centers in Bolivia, a country where Chagas infection remains highly endemic and where the research team has decades of clinical experience. Participants were randomly assigned to one of six treatment groups. Three groups received benznidazole, either as the 60-day standard regimen or as shortened 30-day and extended 90-day courses, while three parallel groups received nifurtimox on the same three schedules. Throughout the study, investigators recorded every drug-related adverse event and periodically tested participants’ blood for parasite DNA using quantitative PCR, a molecular technique sensitive enough to detect residual infection that microscopic or serological methods would miss. The statistical design and analysis were led by the ISGlobal Biostatistics Unit, which also supported an independent board responsible for monitoring patient safety throughout the trial.

The safety results pointed clearly in one direction. Only the 30-day benznidazole regimen significantly reduced side effects: 37 percent of participants on that schedule experienced a drug-related adverse event, compared with 60 percent of those on the standard 60-day course, a reduction of nearly 40 percent. Tolerability translated directly into adherence. On the shorter regimen, 83 percent of patients completed treatment without interruption, versus 60 percent on the standard schedule. An additional practical advantage is that the 30-day course requires only one dose per day rather than two, simplifying life for patients and health systems alike. The researchers also observed that most side effects appeared within the first two weeks of treatment regardless of how long the drug was continued, and that almost all of these reactions resolved, suggesting that the later weeks of the standard course add toxicity without adding early-warning signals.

Crucially, the shorter course did not sacrifice efficacy. Three years after treatment ended, the parasite remained undetectable in the blood of 94 percent of participants in the 30-day benznidazole group, compared with 95 percent in the standard 60-day group. Because the trial was designed as a non-inferiority study, this narrow difference met the prespecified statistical criterion, meaning the shorter regimen could be considered as effective as the established one. Among the six strategies tested, the 30-day benznidazole course therefore offered the best overall balance between benefits and harms. The nifurtimox arms performed less well across the board, with parasite clearance rates ranging from 81 to 90 percent, reinforcing benznidazole’s position as the preferred first-line option where it is available and tolerated.

The implications extend beyond individual patients to the economics and logistics of public health programs. Because the 30-day regimen uses a quarter of the total drug required by the standard course, the same supply of benznidazole can treat four times as many people. Torrico highlighted this point directly, noting that four patients can now be treated with the amount of drug previously needed for one. Gascón added that the improved safety profile, combined with once-daily dosing, has the potential to substantially increase the proportion of patients who complete treatment, which is precisely the bottleneck that has limited the impact of Chagas therapy for decades. For national control programs in Latin America and for growing patient populations in the United States and Europe, a shorter, cheaper and better-tolerated cure could make routine treatment far more feasible.

The authors caution that larger phase 3 trials are needed to confirm the results before the 30-day regimen can be written into official treatment guidelines, and they emphasize that people currently receiving therapy for Chagas disease should continue the regimen prescribed by their doctor. Even so, the trial represents a milestone for a disease long classified as neglected. By demonstrating that a 50-year-old drug can be given more briefly, more conveniently and more safely without losing efficacy, TESEO provides the strongest evidence yet that the barriers keeping millions of people from a cure can be substantially lowered. The study was funded by the National Institute of Allergy and Infectious Diseases, part of the US National Institutes of Health, and is registered as ClinicalTrials.gov NCT03981523. The authors declare no competing interests.

Subject of Research: A randomized phase 2b trial comparing alternative benznidazole and nifurtimox regimens for chronic Trypanosoma cruzi infection

Article Title: A shorter, better-tolerated treatment for chagas disease is possible

Article References: A shorter, better-tolerated treatment for chagas disease is possible. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Chagas disease, Trypanosoma cruzi, benznidazole, nifurtimox, TESEO trial, randomized clinical trial, neglected tropical diseases, ISGlobal, treatment adherence, parasitology, Bolivia, The Lancet Infectious Diseases

The investigation was led by Márcio Galvão Pavan of the Oswaldo Cruz Institute (Fiocruz) in Rio de Janeiro, together with Rodrigo Gurgel-Gonçalves of the University of Brasília and colleagues, including Fernando Abad-Franch and Fernando Araujo Monteiro, who contributed equally to the work. The team set out to answer a deceptively simple question: when light-colored bugs turn up inside carnaúba palms, are they R. nasutus, the species whose primary habitat these palms represent in northeastern Brazil, or could they actually be R. neglectus wearing, in effect, a different species’ colors? The answer, according to the combined genetic and morphological evidence, is frequently the latter.

The study’s foundation lies in an ecological and biogeographical puzzle. Rhodnius nasutus is typical of the Caatinga, Brazil’s seasonally dry, thorny scrubland biome, where it dwells chiefly in the crowns of Copernicia prunifera palms and is characteristically light brown in color. Rhodnius neglectus, by contrast, is a core-Cerrado species associated with Mauritia flexuosa palms and typically shows a much darker brown body. Because the Caatinga and Cerrado intergrade across a broad transition zone, the two palm species, and the bugs that inhabit them, occasionally come into geographic contact. That overlap set the stage for the color confusion the researchers document.

To untangle the situation, the team sampled triatomines from C. prunifera palms across the semiarid Caatinga and the Caatinga-Cerrado transition, comparing them with specimens collected from core-Cerrado M. flexuosa palms. Every insect was first identified by phenotype, meaning its visible color pattern and morphology. The researchers then turned to genetics, sequencing clones of the mitochondrial cytochrome b gene, a standard barcoding marker, and the nuclear ribosomal DNA internal transcribed spacer 2, or ITS2. This two-marker strategy allowed the team to compare signals from the maternally inherited mitochondrial genome with those from the nuclear genome, a contrast that proved decisive.

The morphological results were clear at the extremes but murky in the middle. Adult specimens from core-Cerrado Mauritia palms consistently displayed the dark brown coloration typical of R. neglectus, while adults from core-Caatinga localities showed the light brown hue typical of R. nasutus. But in bugs captured in carnaúba palms from the Caatinga-Cerrado transition zone and parts of the central-western Caatinga, color patterns were dubious, matching neither type reliably. Specimens that looked like typical light brown R. nasutus could not confidently be assigned on appearance alone, raising the possibility that field identifications based on color might have been systematically wrong in exactly these regions.

Genetics began to resolve the ambiguity. Bayesian genealogies built from cytochrome b sequences placed the dubious-phenotype specimens that resembled typical R. nasutus in a sub-clade that is sister to typical R. neglectus from Mauritia flexuosa palms, with roughly 2% mean cytb divergence separating the two sub-clades. In other words, the bugs that looked like R. nasutus carried mitochondrial genomes pointing to R. neglectus ancestry. This mitochondrial signal effectively dissolved the taxonomic uncertainty created by the shared coloration, demonstrating that insects occupying carnaúba palms in the transition zone belong, at least by maternal lineage, with R. neglectus.

The nuclear ITS2 marker told a less tidy story. ITS2 genealogies recovered both R. neglectus and R. nasutus as paraphyletic, meaning individuals of each nominal species were scattered across the gene tree rather than clustering neatly by species. Such patterns often arise when recently diverged species still share ancestral genetic variation. When the researchers applied a multispecies-coalescent analysis, a statistical framework designed to account for this shared ancestry, the dubious-phenotype bugs from C. prunifera clustered with typical R. neglectus. The analysis suggested that the messy ITS2 picture reflects incomplete lineage sorting, the retention of ancestral polymorphisms, rather than hybridization or misassigned species limits. The mito-nuclear discordance observed in the study is thus itself scientifically informative, illustrating how different genomes can carry different historical signals during the early stages of species divergence.

Why would two species converge on the same color? The authors propose that predator-driven natural selection is the most plausible mechanism. Triatomine bugs live in palm crowns where the substrate color is set by the palm’s dried leaf bases and fibers. In the core Cerrado, dark Mauritia crowns favor dark R. neglectus; in the core Caatinga, the lighter carnaúba substrate favors pale R. nasutus. But when R. neglectus colonizes carnaúba palms, individuals whose coloration better matches the light palm-crown substrate presumably enjoy better camouflage against visual predators such as birds and lizards. Over time, this selection pressure could produce R. neglectus populations whose light brown bodies are nearly indistinguishable from typical R. nasutus. This is a textbook scenario of adaptive phenotypic convergence, conceptually related to classic camouflage and mimicry systems in evolutionary biology, but documented here in disease vectors, where species identity has public health consequences.

The practical implications are significant. Chagas disease remains a major neglected tropical disease in Latin America, and surveillance programs depend on correctly identifying which vector species are present in a given area, because species differ in habitat preferences, domestic invasion behavior, and epidemiological relevance. If R. neglectus can masquerade as R. nasutus, field records based on color alone may misattribute vectors to the wrong species and thereby misguide control strategies. The study’s findings, the authors argue, call into question the widespread use of overall body color as a key phenotypic character in triatomine taxonomy. As molecular tools become more accessible, integrating DNA-based confirmation into routine vector surveillance may be essential wherever palm-dwelling Rhodnius species co-occur or share similar microhabitats.

Beyond the immediate applied concerns, the work contributes to a broader understanding of how color variation evolves in triatomines and how convergence can erode the morphological signals taxonomists depend on. The researchers received support from Brazil’s CAPES and CNPq funding agencies, and sampling was conducted under permit from the country’s biodiversity authority, ICMBio. By combining careful field collection across two biomes with mitochondrial and nuclear sequence analysis and modern coalescent modeling, the team has shown that even a character as apparently straightforward as body color can be shaped powerfully by ecology, and that species identities written in DNA may diverge sharply from those written on the insect’s back. For the bugs of the carnaúba palms, looking like the neighbor may be good for survival, but it makes life considerably harder for the scientists trying to tell them apart.

Subject of Research: Phenotypic convergence in the Chagas disease vector bugs Rhodnius neglectus and Rhodnius nasutus inhabiting Copernicia prunifera palms in Brazil

Article Title: Phenotypic convergence in Chagas disease vectors: Rhodnius neglectus from Copernicia prunifera palms may express the typical Rhodnius nasutus color phenotype

Article References: Pavan, M. G., Gurgel-Gonçalves, R., Corrêa-Antônio, J., Morelli, K. A., Bahia, A. C., Abad-Franch, F., & Monteiro, F. A. (2026). Phenotypic convergence in Chagas disease vectors: Rhodnius neglectus from Copernicia prunifera palms may express the typical Rhodnius nasutus color phenotype. Parasites & Vectors. https://doi.org/10.1186/s13071-026-07651-3

Image Credits: AI Generated

DOI: 10.1186/s13071-026-07651-3

Keywords: Triatominae, Rhodnius, Chagas disease, phenotypic convergence, convergent evolution, camouflage, Copernicia prunifera, cytochrome b, ITS2, incomplete lineage sorting, mito-nuclear discordance, Brazil

The stakes of this work are considerable. Leishmaniasis and Chagas disease, caused by trypanosomatid parasites transmitted by sand flies and triatomine bugs respectively, affect millions of people across more than 90 countries, with Brazil among the six most burdened nations. According to the Pan American Health Organization, an estimated 6 to 7 million people are infected with Chagas disease worldwide, with roughly 30,000 new cases and 14,000 deaths each year. Leishmaniasis manifests in clinical forms ranging from disfiguring cutaneous lesions to fatal visceral disease, while chronic Chagas cardiomyopathy can silently progress to heart failure and sudden death decades after the initial infection.

Current therapies fall far short of what clinicians need. Pentavalent antimonials, amphotericin B, miltefosine, benznidazole, and nifurtimox all suffer from significant toxicity, lengthy treatment regimens, variable efficacy depending on disease stage, and rising resistance. This therapeutic gap motivated the research team, led by scientists at the State University of Maringá in Brazil, to screen a panel of four synthetic azobenzenoid compounds—PH011669, S981796, L170224, and CaCS2—against multiple life stages of both parasites using a combination of laboratory and computational approaches.

The in vitro results revealed a striking hierarchy of activity. While PH011669 and S981796 showed no meaningful effect on proliferating promastigotes or epimastigotes, both displayed potent activity against intracellular amastigotes of L. amazonensis, the clinically relevant stage that hides inside host macrophages, with half-inhibitory concentrations below 10 micromolar and selectivity indices exceeding 44. L170224 showed a narrower profile, active against Leishmania but inert against T. cruzi. Only CaCS2 demonstrated broad-spectrum activity across every stage tested: promastigotes and amastigotes of L. amazonensis, and both epimastigotes and bloodstream trypomastigotes of T. cruzi, with inhibitory concentrations ranging from roughly 9 to 22 micromolar.

Just as important as potency was safety. CaCS2 showed remarkably low toxicity toward mammalian cells, with half-cytotoxic concentrations of 428 micromolar against J774A.1 macrophages and 673.5 micromolar against LLC-MK2 epithelial cells, yielding selectivity indices between 30 and 60 depending on the parasite stage. By comparison, the reference drugs miltefosine and benznidazole, though potent in some assays, displayed substantially lower selectivity margins. This favorable therapeutic window prompted the team to focus all subsequent mechanistic work on CaCS2 alone.

The mystery deepened when the researchers considered the compound’s history. CaCS2 was previously identified as an inhibitor of chorismate synthase, an enzyme found in fungi, mycobacteria, plants, and apicomplexan parasites—but not in trypanosomatids. Since T. cruzi and Leishmania lack the chorismate synthase gene entirely, the observed antiparasitic activity could not be explained by the compound’s known mechanism. Something else inside these parasites had to be the target.

To find it, the team turned to a reverse screening strategy called the Similarity Ensemble Approach, which compares the chemical structure of a query molecule against the known ligands of thousands of annotated proteins. The analysis flagged RNA editing ligase 1, or REL1, as a high-confidence candidate, with a statistical significance value of 1.76 × 10⁻¹². REL1 is a compelling target for several reasons: it is indispensable for the uridine insertion and deletion reactions that edit mitochondrial mRNA in trypanosomatids, it cannot be functionally replaced by its partner enzyme REL2, and it has no close homolog in mammalian cells, minimizing the risk of host toxicity.

Using AlphaFold-predicted structures of REL1 from both L. braziliensis and T. cruzi, superimposed onto the crystal structure of the T. brucei enzyme bound to ATP and magnesium, the researchers mapped the enzyme’s binding cavities. Blind docking across 100 simulations revealed that CaCS2 preferentially occupied two pockets: the orthosteric site, where the ATP cofactor normally binds, and an alternative cavity on the opposite face of the protein. Guided docking with three independent programs—AutoDock Vina, AutoDock 4.2.3, and Molegro—consistently ranked CaCS2’s binding at the orthosteric site second only to ATP itself, with the ligand forming hydrogen bonds and electrostatic contacts with key catalytic residues such as Lys42, Arg63, and Phe162 in the Leishmania enzyme, and Ile55, Lys81, and Phe203 in the Trypanosoma version.

Molecular dynamics simulations running 100 nanoseconds for each protein-ligand complex provided the decisive test. The systems reached equilibrium after about 40 nanoseconds, and CaCS2 bound at the orthosteric site remained stably anchored throughout the simulation in both parasite enzymes, mirroring the behavior of ATP. In contrast, the ligand at the alternative site proved transient: it diffused away from the pocket early in the Leishmania simulation, and in the Trypanosoma system it detached before returning after 35 nanoseconds. Analyses of the radius of gyration and per-residue fluctuations confirmed that the protein never unfolded in any complex, and contact-frequency calculations showed that CaCS2 at the orthosteric site shared nine key residues with ATP in both species—far more than the six or seven residues engaged at the alternative site.

Taken together, the evidence suggests that CaCS2 inhibits REL1 by competing with ATP at the catalytic site rather than by acting as an allosteric effector, a conclusion consistent with the compound’s negative net charge, which resembles the charged phosphate backbone that anchors ATP in the pocket. The authors caution that direct enzyme inhibition assays will be needed to confirm the mechanism, but the convergence of broad-spectrum antiparasitic activity, low mammalian cytotoxicity, and stable predicted binding to a parasite-essential, human-absent enzyme makes CaCS2 a promising lead scaffold. As drug resistance continues to erode the value of existing therapies for Chagas disease and leishmaniasis, molecules that exploit the unique biochemistry of RNA editing may offer a much-needed path forward.

Subject of Research: Azobenzenoid derivatives as inhibitors of RNA editing ligase 1 in Trypanosoma cruzi and Leishmania amazonensis parasites

Article Title: Integrated Experimental and Computational Investigation of Azobenzenoid Derivatives Against Trypanosomatid: RNA Editing Ligase 1 as a Potential Molecular Target

Article References: Khan, A., Balbinot, R. B., Lazarin-Bidóia, D., Paetzold, M. G., Seixas, Í. N., Ramos Silva, G. N., Fernandez, M. A., Nakamura, C. V., & Seixas, F. A. V. (2026). Integrated Experimental and Computational Investigation of Azobenzenoid Derivatives Against Trypanosomatid: RNA Editing Ligase 1 as a Potential Molecular Target. Acta Parasitologica, 71(5), Article 201. https://doi.org/10.1007/s11686-026-01391-1

Image Credits: AI Generated

DOI: 10.1007/s11686-026-01391-1

Keywords: Trypanosoma cruzi, Leishmania amazonensis, RNA editing ligase 1, azobenzenoid derivatives, Chagas disease, leishmaniasis, molecular docking, molecular dynamics simulation, drug discovery, neglected tropical diseases, cytotoxicity, CaCS2